Top workplace for nuclear medicine.
In the short period since the company’s inception in 2005, it has become one of the most prominent producers of PET radiopharmaceuticals and providers of outpatient care in the area of nuclear medicine. The examinations of patients using the PET/CT and SPECT/CT tomographs started already in the first year of the company’s operation. At the same time, a trial licensed production of Fludeoxyglucose F18 (FDG) was launched and BIONT company has been supplying every PET centre in Slovakia with FDG since 2006. In 2009, it has started its regular supplies of radiopharmaceuticals abroad too. Naturally, the company complies with the principles of the Good Manufacturing Practices and uses a certified Quality Management System.
BIONT company is aware of its responsibilities regarding the quality of its products and services in radionuclide diagnostics, the production of radionuclides, radiopharmaceuticals, and the application of ionic bonds, and is therefore developing and documenting the Quality Management System in order to fulfil the provisions and legal requirements, satisfy the needs of its customers and improve the company management. The quality system is based on best practices and is subject to the international standard STN EN ISO 9001:2009.
The company’s quality policy monitors the satisfaction rate among patients who have been diagnosed and treated, the company’s personnel, as well as other organisations and citizens living in its proximity.
Producer of radiopharmaceuticals.
BIONT, a.s is a contract manufacturer of FDG for the following companies: Radiomedic, s.r.o., Řež, Czech Republic, and BSM Diagnostica GmbH, Vienna, Austria. The company’s proprietary product – radiopharmaceutical “biontFDG” is registered in six countries of the European Union already. As of 2012, it is produced as a licensed product by Eczacıbaşı-Monrol company in Romania, which is also building further production facilities in Bulgaria and Poland.
In addition to the standard PET/CT scanning using the FDG, BIONT company offers examinations using the 11C-Methionine and is expanding its production with further PET radiopharmaceuticals.